Introduction
Paclitaxel is a tubulin binding drug of the taxane family and exerts its proximal mechanism of action by stabilizing the tubulin polymer during mitotic spindle formation (Horwitz, 1994) . The spindle is unable to depolymerize eectively in the presence of paclitaxel, leading to (or associated with) G2/M arrest and eventual cell death. The inclusion of paclitaxel in the treatment of patients with newly-diagnosed ovarian cancer has lead to improved response rates and prolonged median survivals compared to the results of prior regimens (McGuire et al., 1996) . Nevertheless, the majority of patients with advanced ovarian cancer are destined to relapse, followed by the development of resistance to initially active drugs such as paclitaxel (Cannistra, 1993) . Mechanisms of resistance to paclitaxel have been largely de®ned through in vitro studies and include overexpression of the mdr-1 (gp170) protein (Arceci, 1993) and abnormalities in tubulin expression (Cabral, 1983; Dumontet et al., 1996; Haber et al., 1995) , although the in vivo relevance of these observations remain unclear (Izquierdo et al., 1995) .
Insight into the mechanisms of drug resistance has been gained from a better understanding of the pathway of programmed cell death, or apoptosis. Apoptosis is the ®nal common pathway of many if not all forms of chemotherapy-induced cell death (Fisher, 1994; Lowe et al., 1994) . Molecules known to predispose to apoptosis have been shown to enhance sensitivity to a variety of chemotherapeutic agents which induce damage to DNA or to the mitotic spindle (Dole et al., 1996; Fisher, 1994; Strobel et al., 1996) . Conversely, defects in the apoptotic pathway have been observed to confer insensitivity to the cytotoxic eects of chemotherapy and may therefore represent an important distal mechanism for the development of chemoresistance (Chao et al., 1995; Datta et al., 1995; Dole et al., 1995; Ibrado et al., 1996 Ibrado et al., , 1997 Minn et al., 1995) . The apoptotic response of a cell damaged by chemotherapy partly depends upon the balance between proteins which predispose to programmed cell death, such as BAX, and proteins which antagonize programmed cell death, such as BCL-x L or BCL-2 (Oltvai et al., 1993; Yang and Korsmeyer, 1996) . Each of these proteins is a member of the BCL-2 family of molecules and shares homology in at least three, and often four regions termed the BH1 through BH4 domains (BH; BCL-2 Homology). Many of these proteins, including BCL-2, BCL-x L , and BAX, also contain a hydrophobic carboxy-terminal signal anchor which appears to initiate their localization to the mitochondrial membrane, as well as the outer nuclear envelope and endoplasmic reticulum . Members of the BCL-2 family of proteins are known for their ability to dimerize with one another through interactions involving amino acids contributed by BH1, BH2 and often BH3 domains (Sedlak et al., 1995; Yin et al., 1994; . Overexpression of BAX has been shown to promote the cell death of murine FL5.12 cells after IL-3 withdrawal, an eect which is associated with an excess of BAX:BAX homodimers (Oltvai et al., 1993) . Conversely, overexpression of anti-apoptotic proteins such as BCL-x L represses the death function of BAX, associated with the formation of BCL-x L : BAX heterodimers (or the analogous dimers formed by BCL-2 instead of BCL-x L ) (Oltvai et al., 1993; Yang and Korsmeyer, 1996) . Thus, the ratio of BAX to BCL-x L (or BCL-2) appears to be a critical determinant of the apoptotic threshold, with high BAX to BCL-x L ratios favoring a death response.
We have recently shown that paclitaxel-induced apoptosis of the SW626 ovarian cancer cell line is enhanced by stable BAX overexpression in a p53-independent manner (Strobel T et al., 1996 (Strobel T et al., , 1997b . In this regard, the BAD (BCL-2 Associated Death promoter) protein is a newly described proapoptotic member of the BCL-2 family which is capable of binding to both BCL-x L and BCL-2 and also displaces BAX . BAD contains a BH3 amphipathic helix responsible for its binding to the hydrophobic pocket of BCL-x L and BCL-2 (Zha et al., 1997) . In contrast to BCL-x L and BAX, BAD lacks a carboxy-terminal signal anchor necessary for membrane localization. As such, BAD and molecules such as BID which principally possess the BH3 domain represent death ligands that can translocate between the cytosol and membrane-bound BCL-x L or BCL-2. In this study, we have investigated the possibility that BAD might function as a posttranslational regulator of chemotherapy-induced apoptosis of epithelial ovarian cancer cells. We now present data which suggest that the BAD protein is capable of partly reversing chemoresistance in ovarian cancer in association with BCL-x L binding and disruption of BAX/BCL-x L interaction.
Results
Characterization of HA-BAD expression in stable transfectants of 36M and SW626 human ovarian cancer cell lines 36M and SW626 human ovarian cancer cells were cotransfected with vectors expressing (HA)-tagged murine BAD (HA-BAD) and a neomycin resistance gene, followed by G418 selection and subsequent cloning. Cells transfected with the neomycin resistance gene alone were used as controls. As shown in Figures  1a and b , a total of six clonal HA-BAD transfectants and seven neo-control clones were isolated and characterized for the expression of BCL-2 family proteins by immunoblot. The &32 kDa band of HA-BAD is observed only in cells transfected with the HA-BAD-containing vector. In 36M transfectants, the levels of BAX, BCL-2, and BCL-x L are roughly equivalent in neo-control cells and in HA-BAD transfected cells (Figure 1a ). For SW626 transfectants, the HA-BAD-selected clones may express slightly higher levels of BCL-2 and BCL-x L compared to their neo-control counterparts (Figure 1b) . Total number of viable cells and the percentage of nonviable cells as assessed by trypan blue exclusion were similar for all untreated clones over a 5 day incubation period, suggesting that HA-BAD overexpression did not signi®cantly alter the growth rate of 36M or SW626 transfectants. Finally, since the mdr-1 protein is known to mediate the resistance of multiple structurally unrelated cytotoxic drugs, including paclitaxel, we assessed the expression of this protein in all transfectants by¯ow cytometry with the 4E3 monoclonal antibody which is speci®c for mdr-1 (Arceci, 1993) . The mdr-1 protein was not expressed by any of the clones used in this study (per cent speci®c reactivity with 4E3 antibody 55% for each clone).
HA-BAD overexpression is associated with enhanced sensitivity of ovarian cancer cells to paclitaxel and vincristine
In order to determine the eects of BAD expression on the sensitivity of ovarian cancer cells to paclitaxel, 36M and SW626 transfectants were grown in plastic dishes in the presence of paclitaxel (0-0.2 mM) for 72 h, with the per cent viable cells determined by trypan blue exclusion. Representative data in Figures 2a,b show that HA-BAD transfectants were signi®cantly more sensitive to paclitaxel compared to neo-control clones for both 36M as well as SW626 cells. As shown in Table 1 , the mean LD 50 of paclitaxel in the three 36M neo-control cells was 0.12+0.01 mM, compared to a mean value of 0.036+0.007 mM in the three 36M Figure 1 Expression of HA-BAD in 36M and SW626 transfectants. Cells from the human ovarian cancer cell lines 36M and SW626 were transfected with murine HA-BAD cDNA by lipofection, followed by isolation of G418-resistant clones as described. Expression of BCL-2 family members was determined by immunoblot for either 36M clones (a) or SW626 clones (b), using the signal for a-tubulin to ensure equivalence of protein loading. The molecular masses of the protein species detected are as follows: HA-BAD, 32 kDa; BAX, 21 kDa; BCL-2, 29 kDa; BCL-x L , 32 kDa; tubulin, 55 kDa. The antibody used for detection of murine HA-BAD (clone 48, Transduction Laboratories, Lexington, KY) was raised against the mouse product, which migrates at &32 kDa HA-BAD clones, corresponding to a 3.3-fold enhancement in chemosensitivity (P=0.001, n=6 separate determinations for each group). Mean LD 50 values for SW626 neo-control transfectants compared to HA-BAD cells were 0.13+0.04 mM and 0.035+0.005 mM, respectively, representing a 3.7-fold enhancement of paclitaxel-induced cytotoxicity (P=0.02, n=6 separate determinations for each group). In separate experiments, the eects of HA-BAD on paclitaxel-induced cytotoxicity were also assessed by determining day 10 clonogenic cell survival in soft agar in the continued presence of drug. For 36M HA-BAD cells (clone G3.1), paclitaxel cytotoxicity was enhanced 5.2-fold compared to neo-control clone F4 (Figure 2c ). In addition, DNA histogram analysis was performed in order to assess the eects of BAD on the cell cycle during paclitaxel treatment. When compared to neocontrol cells, HA-BAD cells experienced profound G2/ M arrest in the presence of 0.2 mM paclitaxel at 12 ± 24 h, associated with the appearance of cells containing a sub-G0 content of DNA characteristic of apoptosis at 24 ± 36 h ( Figure 3) . Speci®cally, the percentage of neo clone F4 cells in G2/M after paclitaxel exposure at 12 and 24 h was 18 and 24.7%, respectively (coecient of variation (CV) of 7.4 and 10.1, respectively). Corresponding G2/M values for HA-BAD clone G3.1 were 37.9 and 54.9% (CV of 7.4 and 14.6, respectively). By 36 h, the percentage of cells containing a sub-G0 DNA content ( Figure 3 ) for neo clone F4 and HA-BAD clone G3.1 was 15.2 and 44.4%, respectively. Likewise, the percentage of annexin V reactive cells for neo versus HA-BAD cells was 0.9 and 15.6%, respectively. Finally, the fraction of cells displaying morphologic hallmarks of apoptosis (nuclear fragmentation) for neo versus HA-BAD cells was 3.8+1.9% and 24.3+2.4%, respectively (P=0.0001, mean+s.e.m. of two determinations). Paclitaxel (1.0 mM) did not induce changes in the levels of BAX, BCL-2, or BCL-x L in 36M cells over a 72 h period as assessed by immunoblot analysis, although a slower migrating band consistent with phosphorylated BCL-2 (Blagosklonny et al., 1996; Haldar et al., 1996; Ito et al., 1997) was observed as early as 4 h after paclitaxel exposure in these cells (data not shown).
In order to determine whether the sensitization eect of HA-BAD was observed for other agents, dose response curves were similarly determined for vincristine, carboplatin, and etoposide, with the results summarized in Table 1 . As for paclitaxel, 36M or SW626 cells expressing HA-BAD were sensitized to the eects of the microtubule poison vincristine (5.2-and 3.0-fold enhancement, respectively, P=0.001). The eects of HA-BAD expression on the cytotoxicity of etoposide was less consistent and less pronounced, with 36M cells demonstrating an &2.0-fold enhancement and SW626 cells showing no eect. Finally, 36M and SW626 HA-BAD-expressing clones were not sensitized to the cytotoxicity of carboplatin, a DNA-damaging agent. This pro®le of sensitization to drugs which target tubulin has been previously observed for cells which overexpress BAX (Strobel et al., 1996 (Strobel et al., , 1997b Figure 2 Dose-response curves for 36M and SW626 transfectants in the presence of paclitaxel. Representative HA-BAD transfectants of 36M and SW626 cells were grown in plastic dishes (a and b) or in semisolid medium (c) in the presence of varying concentrations of paclitaxel as indicated. Viability was assessed by trypan blue exclusion at day 3 for (a and b), or by quantitation of colonies containing more than 10 cells at day 10 for (c) Cells were grown at subcon¯uent density in plastic wells over a 3 day period in the presence of various drugs as indicated, followed by trypsinization and assessment of viability by trypan blue exclusion. LD50 values re¯ect the amount of drug necessary to achieve 50% cell kill compared to cells grown in media alone. Data are expressed as mean+s.e.m LD50 for either neo-control clones (n=3 for 36M, n=4 for SW626) or HA-BAD clones (n=3 for both cell types) as indicated.
b P values determined by two-sided student's t-test. Signi®cant enhancement of cytotoxicity was observed in 36M and SW626 HA-BAD expressing clones treated with paclitaxel and vincristine. Enhancement of etoposide cytotoxicity was noted only for 36M cells, and no enhancement was observed for either clone in response to carboplatin (CBDCA) and suggests that BAD may mediate its eects through a BAX-dependent pathway.
HA-BAD prevents association between BCL-x L and BAX
In FL5.12 cells, expression of HA-BAD has been shown to enhance apoptosis through binding to BCLx L or BCL-2, in association with displacement of BAX . In order to determine whether HA-BAD could disrupt BCL-x L /BAX interaction in ovarian cancer cells, whole cell lysates of S 35 -methionine-labeled cells were immunoprecipitated with either anti-BCL-x L or anti-BAX antibody, followed by SDS ± PAGE and autoradiography, with the results of a representative experiment for 36M cells shown in Figure 4 . In 36M neo-control cells (clone F4), immunoprecipitation with anti-BCL-x L antibody revealed the expected &32 kDa band for BCL-x L as well as an associated band at 21 kDa consistent with BAX ( Figure 4 ). This 21 kDa band was determined to represent BAX on the basis of sequential immunoprecipitation of S 35 -methioninelabeled 36M cells using anti-BCL-x L followed by anti-BAX antibodies (data not shown). Likewise, performing immunoprecipitation in the reverse direction using an anti-BAX antibody revealed the expected 21 kDa species for BAX, as well as an associated 32 kDa protein consistent with BCL-x L . In contrast, 36M cells expressing HA-BAD (clone G3.1) immunoprecipitated with anti-BCL-x L antibody revealed no evidence of associated BAX, and performing immunoprecipitation using anti-BAX antibody revealed decreased amounts of associated BCL-x L (Figure 4) . By densitometry analysis, BCL-x L represented a mean of 36+8% (range 25 ± 53%) of the combined species (BAX plus BCL-x L ) immunoprecipitated with anti-BAX antibody in neo-control cells (clones C7, F4, and H2, n=7 dierent experiments).
By comparison, BCL-x L comprised a mean of 21+6% (range 14 ± 27) of the combined signal in HA-BAD clones E3, F5, and G3.1 (P=0.02, n=4 experiments). Similar results were observed for SW626 transfectants (data not shown). Interestingly, we never observed the characteristic 29 kDa of BCL-2 associated with BAX in anti-BAX immunoprecipitates of 36M or SW626 (Figures 1 and 4) . Also, in contrast to the results of anti-BCL-x L , immunoprecipitation using anti-BCL-2 antibody did not reveal an associated 21 kDa protein consistent with BAX ( Figure 5) . Thus, the majority of BAX is associated with BCL-x L , as opposed to BCL-2, in 36M and SW626 cells. These data suggest that the BCL-x L :BAX heterodimer is disrupted in cells which express HA-BAD. In order to determine whether this re¯ects the formation of a heterodimer between HA-BAD and BCL-x L , we performed IP/immunoblot analysis using anti-BCL-x L or anti-HA antibodies for immunoprecipitation and a biotinylated anti-BAD antibody for immunoblot development. As shown in Figure 6 , immunoprecipitation with anti-BCL-x L antibody followed by anti-BAD immunoblot analysis reveals a band at 32 kDa which is the predicted size for murine HA-BAD (both human BCL-x L and murine HA-BAD migrate at &32 kDa). Con®rmation of the identity of this band as HA-BAD is provided by ®nding a similar 32 kDa band upon immunoprecipitation with anti-HA antibody, followed by immunoblot using anti-BAD antibody ( Figure 6 ).
Endogenous human BAD expression in ovarian cancer cell lines and fresh tumor cells
In order to determine whether endogenous BAD could be expressed in human ovarian epithelial cells, immunoblotting was performed on ®ve dierent ovarian cancer cell lines as well as primary ovarian cancer samples derived from malignant ascites, using a rabbit polyclonal antibody which recognizes human BAD (Figure 7) . The predicted 29 kDa species of human BAD was easily detectable in SW626 and OVCAR-3 cells, as well as in each primary tumor sample, and was weakly expressed in CAOV-3 cells. BAD protein was undetectable in 36M and SKOV-3 cells. Thus, the presence of BAD protein in transformed cells of ovarian epithelial origin suggests the possibility, but does not prove, that this molecule might function as a physiologic regulator of paclitaxel response in at least some circumstances. Immunoprecipitates using either anti-BCL-2 antibody (clone 124) or rabbit anti-human BAX polyclonal antibody as a positive control, followed by autoradiography. Anti-D144 and RaS were used as negative controls for immunoprecipitation with BCl-2 and BAX antibodies, respectively. BAX was not detectable in BCL-2 immunoprecipitates, despite ample amounts of BCL-2 protein in both cell types
Discussion
Prior studies in murine hematopoietic cells indicate that apoptosis is enhanced when more than half of total cellular BAX is released from BCL-x L or BCL-2 heterodimers (Oltvai et al., 1993) . This observation has lead to the suggestion that the anti-apoptotic eects of BCL-x L and BCL-2 may be partly related to BAX sequestration and, perhaps, decreased formation of BAX homodimers (Oltvai et al., 1993; Yang et al., 1995) . In addition, mutation within the BH1 or BH2 domains of BCL-2 which prevent its heterodimerization with BAX also eliminate BCL-2's protective eect (Yin et al., 1994) . A simple direct relationship between release of BAX and apoptosis is not always observed, however, since mutations in the BH1 or BH2 regions of BCL-x L which disrupt heterodimer formation with BAX do not always diminish the anti-apoptotic eect of this protein (Cheng et al., 1996) . Moreover, gain and loss of function genetic models argue that BCL-2 and BAX can function independently of one another, supporting both an intrinsic anti-apoptotic role for BCL-2 as well as an active pro-apoptotic role for BAX under some circumstances (Knudson and Korsmeyer, 1997) . Nevertheless, a high ratio of BAX to either BCL-2 or BCL-x L has been consistently observed to favor apoptosis in many cell types, suggesting that the amount of`free' BAX is one important factor in determining the apoptotic set point.
In view of the importance of the apoptotic threshold as a determinant of chemotherapy-induced cytotoxicity, a better understanding of mechanisms by which molecules such as BCL-x L and BAX are regulated might permit the development of novel treatment approaches capable of overcoming drug resistance. For this purpose we chose to investigate the role of the BAD molecule as a potential regulator of BCL-x L function in view of its known ability to promote apoptosis in hematopoietic cells through a mechanism involving BH3-dependent binding to BCL-x L Zha et al., , 1997 . By generating several clonal transfectants which overexpress HA-BAD, we have shown that BAD is capable of enhancing chemotherapy-induced apoptosis in a manner that is consistent with a BAX-dependent mechanism. For instance, multiple stable transfectants of 36M and SW626 epithelial ovarian cancer cells which overexpress HA-BAD exhibit enhanced cytotoxicity and G2/M arrest in response to tubulin-damaging drugs such as paclitaxel and vincristine, but not to the DNA damaging agent CBDCA. As we have previously reported, a similar pattern of sensitivity is characteristic of cells which overexpress BAX and suggests that BAD may be mediating its eects through BAX (Strobel et al., 1996) . This is consistent with the fact that BAD alone, in the absence of BCL-x L , is incapable of promoting apoptosis of FL5.12 cells, suggesting that the death promoting eects of this molecule are indirect . The fact that BAX and, indirectly, BAD are capable of accentuating the G2/M arrest after tubulin damage (Figure 3) is consistent with a possible role for these molecules as G2/M checkpoint regulators which partly determine whether a cell is capable of safely progressing through G2/M into G1. The use of several clones generated from two distinct cell lines which do not express the mdr-1 protein further support the interpretation that the observed eect is mediated by BAD and is not an artifact of clonal selection, for instance. Overexpression of HA-BAD was also demonstrated to result in dissociation of endogenous BAX from BCL-x L (Figure 4 ), in conjunction with the formation of HA-BAD : BCL-x L heterodimers ( Figure 6 ). Taken together, these observations suggest that the mechanism by which BAD sensitizes cells to chemotherapy-induced apoptosis may involve release of BAX from BCL-x L and/or inhibition of the protective eects of BCL-x L . The crystal and NMR structure of BCL-x L suggest that a hydrophobic pocket is formed by the BH1, BH2, and BH3 domains and serves as a binding site for associated molecules utilizing the amphipathic BH3 Figure 6 HA-BAD forms a heterodimer with BCL-x L in 36M cells. In order to determine whether HA-BAD was associated with BCL-x L in 36M transfectants, immunoprecipitation with either anti-BCL-x L or anti-HA antibodies was performed, followed by immunoblot with anti-BAD antibody. Isotypespeci®c non-reactive antibodies were used as controls. Immunoblot analysis reveals the expected 32 kDa species for HA-BAD which co-immunoprecipitates with anti-BCL-x L antibody. The identical species is observed upon immunoprecipitation with anti-HA antibody Figure 7 Endogenous human BAD expression in ovarian cancer cell lines and fresh tumor cells. Immunoblotting was performed using a rabbit polyclonal anti-human BAD antibody raised against the LWAAQRYGRELRRMSDEF peptide sequence in order to determine whether human BAD protein could be endogenously expressed in malignant ovarian epithelial cells. Ascites samples 1 ± 3 were obtained from patients with newlydiagnosed epithelial ovarian cancer (papillary serous histology) and contained 490% tumor cells. The blot was stripped and reprobed with murine anti-human a tubulin antibody to assess protein loading domain of BAD or BAX (Muchmore et al., 1996) . Thus, small molecule drugs which can target this pocket might also be capable of inhibiting BCL-x L or displacing BAX, thereby predisposing to apoptosis in the presence of a cytotoxic agent such as paclitaxel. Our data suggest that eorts to design small molecules which can overcome drug resistance by mimicking the eects of BAD may lead to the development of a novel class of drugs for the treatment of cancer.
Materials and methods

Source of cells and reagents
The SW626 human ovarian epithelial carcinoma cell line used for transfection and drug sensitivity studies was obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). The 36M cell lines were derived in our laboratory from a patient with papillary serous ovarian cancer and has been previously reported Strobel et al., 1997a) . We have determined that the p53 gene in both of these cell lines harbors a G ± A mutation at codon 245, resulting in a glycine ± serine substitution. This is consistent with our previous report demonstrating inability to transactivate p21 in SW626 cells upon treatment with ionizing radiation (Strobel et al., 1997b) . Other human ovarian cancer cell lines used in the characterization of endogenous BAD expression were CAOV-3, OVCAR-3, and SKOV-3 (ATCC). In some cases, lysates from malignant ovarian cancer ascites containing 490% tumor cells were used to assess BAD expression by immunoblot as described. Collection and storage of patient cells was conducted as previously described and in accordance with Institutional Review Board approval . Cells were cultured in Dulbecco's modi®ed Eagle's medium (DMEM, Sigma Chemical Company, St. Louis, MO, USA) supplemented with 10% fetal calf serum (FCS) (HyClone, Logan, UT). Iscove's modi®ed Dulbecco's minimal essential medium (IMDMEM) for agar colony assay was purchased from Gibco BRL (Life Technologies, Inc., Gaithersburg, MD, USA). Propidium iodide used for assessment of DNA content was purchased from Sigma. Paclitaxel, carboplatin (CBDCA), and etoposide were purchased from Bristol-Myers Squibb (Princeton, NJ, USA). Vincristine was purchased from Eli Lilly (Indianapolis, IN, USA). Geneticin (G418) used for selection of neomycin resistance during transfection studies was purchased from Gibco BRL. For some experiments, annexin V-FITC conjugate (Pharmingen, San Diego, CA, USA) was used for¯ow cytometric detection of apoptotic cells as previously described (Koopman et al., 1994) .
Generation of stable transfectants expressing HA-BAD
Lipofection was used to generate stable 36M and SW626 clones expressing either pSV2-neo cDNA (a kind gift of Dr Michel Streuli, Dana-Farber Cancer Institute, Boston, MA, USA) or murine BAD cDNA present in an hemagglutinin (HA)/pSFFV-expression vector (HA-BAD) as previously described (Strobel et al., 1996; Yang et al., 1995) . After incubation of transfected cells for up to 3 weeks, neomycin-resistant cells were identi®ed and cloned by limiting dilution.
Antibodies
Primary antibodies used for characterization of 36M and SW626 transfectants in immunoblot analysis are as follows: Rabbit anti-human BAX polyclonal antibody (Ab) (1 : 1000 dilution, clone P19, Santa Cruz Biotechnology, Santa Cruz, CA, USA); murine anti-murine BAD Ab (1 : 1000 dilution, clone 48, Transduction Laboratories, Lexington, KY, USA); rabbit polyclonal Ab against human BAD peptide (LWAAQRYGRELRRMSDEF, 1 : 2500 dilution) raised by one of us (SK); anti-human BCL-2 Ab (either murine clone 124, IgG1, Dako Corporation, Santa Barbara, CA, USA or hamster clone 6C8 (Oltvai et al., 1993) as indicated); rabbit anti-human BCL-x L Ab (1 : 1000 dilution, clone S18, Santa Cruz Biotechnology); murine anti-human a-tubulin Ab (1 : 10 000 dilution, Sigma). Secondary antibodies were either goat anti-rabbit-Ig conjugated to horseradish peroxidase (HRPO) (1 : 3000 dilution), goat anti-mouse Ig conjugated to HRPO (1 : 3000 dilution), or goat antihamster Ig conjugated to HRPO (1 : 3000) as appropriate (Caltag Laboratories, South San Francisco, CA, USA). For immunoprecipitation studies, the following additional antibodies were used: rabbit anti-human BAX (Pharmingen, San Diego, CA, USA); murine anti-human BCL-x L polyclonal Ab (IgG3, clone 7B2, a kind gift of Craig Thompson, University of Chicago, USA); rabbit antihuman BCL-x L polyclonal Ab (Transduction Laboratories); rabbit pre-immune immunoglobulin fraction (for IP control, Dako); murine non-reactive IgG3 Ab (control for 7B2, clone FLOPC-21, Sigma); murine non-reactive IgG1 Ab (clone D144) ; murine anti-HA monoclonal Ab (1 : 2000 dilution, IgG2b, clone 12CA5, Boehringer Mannheim, Indianapolis, IN, USA); murine anti-human CD33 (IgG2b, clone 906, control for anti-HA antibody, a kind gift of Dr James D Grin, DFCI). The 4E3 murine anti-human mdr-1 Ab reactive with P-glycoprotein was used in¯ow cytometric analysis as previously described (Arceci, 1993) and was a kind gift of Dr Robert Arceci (University of Cincinnati, USA).
Cytotoxicity assessment
The relationship between drug dose and cytotoxicity was determined for each transfectant in suspension culture during continuous exposure to drug. Cells were seeded (2.5610 4 /well) in 24 well plates (Falcon, Oxnard, CA, USA) in 10% FCS/DMEM in the presence or absence of a variety of cytotoxic drugs over a broad concentration range, followed by incubation (378C, 5% CO 2 ) and assessment of viable cell numbers by trypan blue exclusion at day 3. Cell counts were performed in duplicate for each drug dose and time point, with the standard error of the mean typically being less than 20%. The per cent survival was de®ned as 1006(viable cell number (drug)/viable cell number (medium)) at the identical time point. For selected experiments clonogenic cell survival was also determined in agar culture over a 10 day incubation as previously described (Cannistra et al., 1985) .
Detection of sub-G0 DNA content by propidium iodide staining
The fraction of cells containing a sub-G0 DNA content has been shown to correlate with apoptotic cell death and was assessed by¯ow cytometry as previously described (Strobel et al., 1996) . Brie¯y, 0.5610 6 cells per sample were pelleted and resuspended in 50 mg/ml PI (Sigma) in 0.1% sodium citrate and 0.1% Nonidet P40 (NP40), resulting in lysis of the cell membrane while maintaining integrity of the nucleus. After a 10 min incubation at RT, 10 000 cells per sample were analysed by¯ow cytometry on an Epics V cell sorter, with quantitation of the fraction of cells present in the sub G0/G1 peak. The Multicycle software program (Multiple option cell cycle analysis, Phoenix Flow Systems, San Diego, CA, USA) was used for curve ®tting in order to quantitate the fraction of cells in the G2/M phase of the cell cycle.
Immunoblotting
Immunoblot analysis was performed as previously described (Strobel et al., 1996) , using the enhanced chemiluminescence (ECL) detection system (Amersham) according to the manufacturer's protocol and exposed to X-ray ®lm (Eastman Kodak). For some experiments involving immunoprecipitation (IP) followed by immunoblotting, it was necessary to biotinylate the antibody used in the immunoblotting step in order to avoid competing signals from the presence of the antibody used for the original immunoprecipitation. For this purpose, protein Gsepharose beads (Pharmacia Biotech, Piscataway, New Jersey, USA) were washed three times with 16phos-phate-buered saline (PBS) (pH 7.2) and incubated with antibody for 1 h at RT with gentle rocking. The antibodycoupled beads were washed three times with 100 mM bicarbonate buer (pH 8.6) and incubated with sNHSBiotin (Pierce Chemical Company, Rockford, IL, USA) in 100 mM bicarbonate buer (pH 8.6) for 4 h at RT on a shaker. Unincorporated biotin was removed by three washes with PBS. The biotinylated antibody was eluted three times with 100 mM Glycin (pH 2.6) supplemented with 0.3 mg/ml bovine serum albumen (BSA) for 5 min at RT. The eluates were combined and the pH was neutralized by adding 1 M Tris pH 8.0. The eluate was desalted and concentrated by three washes in PBS, using a Centricon-10 centrifugal concentrator (Amicon, Beverly, MA, USA). The biotinylated antibody solution was supplemented with BSA (1 mg/ml) and NaN 3 (0.1%) and stored at 48C. For immunoblots using a biotinylated primary antibody, development was performed by adding an avidin/biotinylated HRPO mixture (VECTASTAIN 1 , Vector Laboratories, Burlingame, CA, USA) per the manufacturer's instructions, followed by ECL detection as outlined above.
Metabolic labeling and immunoprecipitation (IP)
The association between BCL-x L and BAX was studied by performing immunoprecipitation of S 35 -methionine-labeled cells. Prior to metabolic labeling, cells were washed twice in prewarmed, serum-free, methionine-free Dulbecco's modi®ed Eagle's medium (Life Technologies, Inc.). For each sample 15610 6 cells were labeled for 4 h with 400 mCi of S35-Express protein labeling mix (New England Nuclear, Boston, MA, USA). All subsequent steps were carried out on ice or in the cold room at 48C. Cells were washed three times with cold phosphate-buered saline and lysed in an NP-40 isotonic lysis buer with freshly added protease inhibitors (142.5 mM KCl, 5 mM MgCl 2 , 10 mM HEPES [pH 7.2], 1 mM EGTA, 0.2% NP-40, 1 mM phenylmethylsulfonyl¯uoride, 7.5 mg/ml aprotinin, 40 mM leupeptin, 5 mM sodium vanadate, 20 mM sodium¯uoride) for 30 min. Nuclei and unlysed cellular debris were removed by centrifugation at 15 000 g for 15 min. Lysates were precleared with proteinA-sepharose for 60 min, which was removed by centrifugation at 400 g for 2 min. Speci®c antibodies were added as indicated for 90 min, and immunoprecipitates were captured with protein A-sepharose for 60 min. Immunoprecipitates were washed twice in lysis buer, solubilized with SDS ± polyacrylamide gel electrophoresis sample buer by boiling for 10 min at 1008C, and separated through 12.5% SDS ± polyacrylamide gels. Gels containing S 35 -methionine-labeled proteins were ®xed with 5% glacial acetic acid and 10% ethanol for 30 min, washed with water for 30 min, and enhanced by impregnating with a commercial enhancing solution (Auto¯uor, National Diagnostics) for 30 min. Gels were then dried, and autoradiography was performed at 7708C.
Statistical analysis
Data are expressed as mean+standard error of the mean (s.e.m.) where appropriate. Signi®cance levels for comparison of dierences were determined using the two-sided Student's t-test for unpaired samples.
